Lexaria Bioscience Corp. Forecasted to Post Q3 2024 Earnings of ($0.13) Per Share (NASDAQ:LEXX)

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Investment analysts at Zacks Small Cap issued their Q3 2024 earnings per share estimates for shares of Lexaria Bioscience in a research note issued to investors on Monday, April 29th. Zacks Small Cap analyst J. Vandermosten forecasts that the company will post earnings of ($0.13) per share for the quarter. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.60) per share. Zacks Small Cap also issued estimates for Lexaria Bioscience’s Q4 2024 earnings at ($0.13) EPS and FY2026 earnings at ($0.36) EPS.

Separately, Maxim Group upped their price target on shares of Lexaria Bioscience from $3.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, March 5th.

Lexaria Bioscience Price Performance

Shares of NASDAQ LEXX opened at $2.46 on Tuesday. The company’s 50-day moving average price is $3.15 and its 200 day moving average price is $2.07. Lexaria Bioscience has a 52 week low of $0.65 and a 52 week high of $6.85.

Institutional Investors Weigh In On Lexaria Bioscience

Large investors have recently bought and sold shares of the stock. Armistice Capital LLC acquired a new position in shares of Lexaria Bioscience in the third quarter worth $889,000. Cowen AND Company LLC acquired a new stake in shares of Lexaria Bioscience during the fourth quarter valued at $320,000. Finally, Welch Group LLC purchased a new stake in Lexaria Bioscience during the 1st quarter worth about $87,000. Institutional investors and hedge funds own 13.06% of the company’s stock.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.